View the latest study results presented at the European Society of Medical Oncology (ESMO) Congress 2025. Intended for healthcare professionals. View Presentation

OUR THERAPYClinical and Scientific Publications

Prospective Studies

An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma

2025 | Zager et al.

Read more

Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study

2024 | Zager et al.

Read more

Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study

2020 | Meijer et al.

Read more

Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan

2017 | de Leede et al.

Read more

Cohort & Case Studies

Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis

2025 | Tong et al.

Read more

Hepatic chemosaturation with melphalan in patients with primary or secondary liver tumors with or without extrahepatic tumor manifestation

2024 | Veelken et al.

Read more

Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience

2022 | Dewald et al.

Read more

New Perspectives in Unresectable Cholangiocarcinoma? Evaluation of Chemosaturation with Percutaneous Hepatic Perfusion as a Palliative Treatment Option

2022 | Dewald et al.

Read more

Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma

2022 | Modi et al.

Read more

Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases

2021 | Bethlehem et al.

Read more

Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden

2020 | Brüning et al.

Read more

Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma

2020 | Schönfeld et al.

Read more

Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience

2019 | Artzner et al.

Read more

Percutaneous Hepatic Perfusion with Melphalan in Uveal Melanoma: A Safe and Effective Treatment Modality in an Orphan Disease

2017 | Karydis et al.

Read more

Scientific Meetings

Melphalan/Hepatic Delivery System versus Best Available Care in Patients with Unresectable Metastatic Uveal Melanoma: Randomized FOCUS Trial Results

ASCO 2024 | Zager et al.

Read more

Subgroup Analysis of FOCUS Phase 3 Trial Efficacy Results

ESMO 2023 | Wheater et al.

Read more

FOCUS Phase 3 Trial Results: Percutaneous Hepatic Perfusion (PHP) With Melphalan for Patients With Ocular Melanoma Liver Metastases (PHP-OCM-301/301A)

ASCO 2022 | Zager et al.

Read more

Isolated Hepatic Perfusion (IHP)

Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases

2025 | Olofsson Bagge et al.

Read more